With a share price down 99.5% from its early 2019 highs, $225 million in sales, and $818 million in annual losses, on the surface at least, Canadian marijuana stock Aurora Cannabis (NASDAQ: ACB) stock does not look much like a screaming buy right now. Aurora Cannabis reported earnings for the second quarter of its fiscal 2024, ended Sept. 30, 2023, in November. The company recorded $46.9 million in sales (as converted into U.S. dollars), spent $21.4 million on cost of goods sold, and thus booked $25.5 million in gross profit -- its highest level of gross profitability since mid-2020.

Continue reading